Enovis Corporation $ENOV Shares Sold by Royce & Associates LP

Royce & Associates LP lowered its stake in shares of Enovis Corporation (NYSE:ENOV) by 70.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 721,240 shares of the company’s stock after selling 1,697,683 shares during the period. Royce & Associates LP owned 1.26% of Enovis worth $21,882,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. AQR Capital Management LLC grew its holdings in shares of Enovis by 12.5% during the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock worth $2,363,000 after purchasing an additional 7,072 shares during the period. Goldman Sachs Group Inc. lifted its position in Enovis by 37.6% in the first quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock valued at $10,226,000 after buying an additional 73,116 shares during the last quarter. Empowered Funds LLC boosted its stake in Enovis by 13.0% during the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after buying an additional 749 shares during the period. State of New Jersey Common Pension Fund D increased its position in shares of Enovis by 30.9% during the second quarter. State of New Jersey Common Pension Fund D now owns 58,185 shares of the company’s stock valued at $1,825,000 after acquiring an additional 13,744 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its position in shares of Enovis by 26.9% during the second quarter. Envestnet Asset Management Inc. now owns 427,183 shares of the company’s stock valued at $13,396,000 after acquiring an additional 90,472 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Price Performance

Enovis stock opened at $25.49 on Monday. The company has a current ratio of 2.02, a quick ratio of 1.04 and a debt-to-equity ratio of 0.85. The company has a fifty day simple moving average of $24.27 and a 200-day simple moving average of $28.18. The stock has a market cap of $1.46 billion, a P/E ratio of -1.23 and a beta of 1.46. Enovis Corporation has a 12-month low of $21.00 and a 12-month high of $40.69.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.81 by $0.14. The company had revenue of $575.76 million for the quarter, compared to analysts’ expectations of $584.30 million. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.Enovis’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the firm earned $0.98 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities analysts expect that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ENOV. Evercore reaffirmed an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. BTIG Research lifted their target price on Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday. UBS Group reiterated a “buy” rating and set a $50.00 price target on shares of Enovis in a research note on Monday, January 5th. Canaccord Genuity Group lowered their price objective on shares of Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, December 17th. Finally, Wells Fargo & Company upped their target price on shares of Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $47.43.

Insiders Place Their Bets

In related news, EVP Daniel A. Pryor sold 999 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total value of $27,172.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.70% of the stock is currently owned by insiders.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.